Belgian drugmaker UCB has entered into an agreement to licence Antengene’s experimental autoimmune disease therapy ATG-201 and associated technology, paying $60 million up front and over $1.1 billion more if certain milestones are met, the Chinese drugmaker said Wednesday.
The deal underscores the “unique” capabilities of a development platform from Antengene, it said in a statement on its website. The company’s Hong Kong-listed shares were up around 6% on Wednesday morning.
ATG-201 targets B-cell-related autoimmune diseases. Antengene plans to submit clinical trial applications in Australia and China in the first quarter of 2026 and after completing phase I trials it will transfer further development to UCB.
Under the agreement with UCB, Antengene is eligible to receive an upfront fee of $60 million and additional payments tied to “certain conditions,” development and commercial-related milestones, plus additional royalties based on net sales.
The agreement covers the development, manufacturing and commercialization of ATG-201 and access to associated manufacturing technology. UCB has been granted a worldwide licence for ATG-201.
(Reporting by Andrew Silver; Editing by Thomas Derpinghaus)
Comments